| Original language | English |
|---|---|
| Pages (from-to) | 2545-2548 |
| Number of pages | 4 |
| Journal | Advances in therapy |
| Volume | 40 |
| Issue number | 5 |
| Early online date | 2023 |
| DOIs | |
| Publication status | Published - May 2023 |
Keywords
- Advanced hybrid closed-loop
- Cost-effectiveness
- Netherlands
- Type 1 diabetes
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Advances in therapy, Vol. 40, No. 5, 05.2023, p. 2545-2548.
Research output: Contribution to journal › Letter › Academic › peer-review
TY - JOUR
T1 - Response to
T2 - Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands
AU - Serné, Erik H.
AU - Roze, Stéphane
AU - Buompensiere, Maria I.
AU - Valentine, William J.
AU - de Portu, Simona
AU - de Valk, Harold W.
N1 - Funding Information: Funding for this response letter was provided by Medtronic International Trading Sàrl. Medical writing and editorial support for the response letter was provided by Richard Pollock at Covalence Research Ltd. All authors contributed to the response letter. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Erik H Serné is an employee of Amsterdam UMC. Stéphane Roze is an employee of Vyoo Agency. Maria Ida Buompensiere and Simona De Portu are employees of Medtronic International Trading Sàrl. William Valentine is a director and employee of Ossian Health Economics and Communications GmbH, which received consulting fees to support preparation of the cost-effectiveness manuscript. Harold W de Valk is an employee of University Medical Center, Utrecht. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Funding Information: Funding for this response letter was provided by Medtronic International Trading Sàrl.
PY - 2023/5
Y1 - 2023/5
KW - Advanced hybrid closed-loop
KW - Cost-effectiveness
KW - Netherlands
KW - Type 1 diabetes
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149578212&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36892809
U2 - https://doi.org/10.1007/s12325-023-02431-2
DO - https://doi.org/10.1007/s12325-023-02431-2
M3 - Letter
C2 - 36892809
SN - 0741-238X
VL - 40
SP - 2545
EP - 2548
JO - Advances in therapy
JF - Advances in therapy
IS - 5
ER -